(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 9.39% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Exact Sciences's revenue in 2025 is $3,082,033,000.On average, 28 Wall Street analysts forecast EXAS's revenue for 2025 to be $609,908,108,262, with the lowest EXAS revenue forecast at $584,329,483,032, and the highest EXAS revenue forecast at $630,939,422,340. On average, 28 Wall Street analysts forecast EXAS's revenue for 2026 to be $685,317,684,866, with the lowest EXAS revenue forecast at $633,781,491,810, and the highest EXAS revenue forecast at $728,517,140,810.
In 2027, EXAS is forecast to generate $765,464,043,920 in revenue, with the lowest revenue forecast at $668,075,796,748 and the highest revenue forecast at $819,463,363,850.